Millennium Pharmaceuticals MLNM
-
SEC charges insider trading in Takeda pharma deal
NEW YORK (Reuters) - U.S. market regulators charged a former employee of Takeda Pharmaceutical Co Ltd with making $63,000 in illegal profits on inside information about the company's 2008 agreement to acquire Millennium Pharmaceuticals Inc.
-
New Morningstar Analyst Report - Alnylam Pharmaceuticals, Inc.
… bring the firm to a good level of stewardship. John Maraganore had senior management-level experience at Millennium Pharmaceuticals before joining Alnylam as CEO shortly after its founding in 2002. Founders of Alnylam remain on the firm …
-
Freeman: The Next Growth Opportunities… purchased ImClone, which we had owned since the 1990s; and Takeda, within the last couple of years, bought Millennium Pharmaceuticals . The tendency is big drug companies have in some cases fallow pipelines, and the biotech companies, looking …
since the 1990s; and Takeda, within the last couple of years, bought Millennium Pharmaceuticals . The tendency is big drug companies have in some cases fallow pipelines, and the biotech companies, looking at the prices today, the -
New Morningstar Analyst Report - Alnylam Pharmaceuticals, Inc.
… bring the firm to a good level of stewardship. John Maraganore had senior management-level experience at Millennium Pharmaceuticals before joining Alnylam as CEO shortly after its founding in 2002. Two founders remain on the firm's board …
-
Mystery Bidder Tops Bristol's Imclone Bud
… acquisitions this year, and we think a firm such as Takeda, which recently acquired cancer-focused firm Millennium Pharmaceuticals and also recently discontinued development of its own EGFR antibody (a similar drug to Imclone's Erbitux …
-
Takeda to Buy Millennium
Millennium Pharmaceuticals MLNM has received an all-cash buyout offer of $8.8 billion, or $25 per share, from Japanese pharma giant Takeda. We think shareholders …
-
Pharmion to Boost Celgene's Growth
… well as a large-scale trial for Revlimid in newly diagnosed multiple myeloma. Although Celgene is slightly behind Millennium MLNM in this indication--which expects first-line approval for Velcade by June--Revlimid already has relatively strong data …
-
Millennium Poised for Growth in 2008
Millennium Pharmaceuticals MLNM wrapped up 2007 with strong sales growth for key cancer drug Velcade and high expectations for an expanded approval in 2008. The …
-
New Data for Competing Cancer Drugs
… released at this year's annual meeting of the American Society of Hematology for Celgene's CELG Revlimid and Millennium's MLNM Velcade only confirm this fact. Because we've already factored Velcade's growing potential as a first-line treatment option …
-
Millennium under Review
We're putting Millennium Pharmaceuticals MLNM under review as we incorporate its strong third-quarter performance and recent positive clinical data for blood cancer drug Velcade into our model. We'll publish a new report shortly.